Your session is about to expire
← Back to Search
Intranasal Scopolamine + Sensory Augmentation for Motion Sickness
Study Summary
This trial will evaluate a nasal gel and sensory belt to reduce motion sickness and improve sensorimotor performance. The gel is a safe, non-invasive way to self-administer with quick results.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I tested negative for COVID-19 recently or have had no symptoms for 10 days.I do not have conditions like glaucoma or issues with urination that could worsen with scopolamine.
- Group 1: Placebo Comparator and Sensory Augmentation Placebo Nasal Gel
- Group 2: DPI-386 Nasal Gel
- Group 3: Placebo Comparator
- Group 4: DPI-386 Nasal Gel and Sensory Augmentation DPI-386 Nasal Gel, 0.4 mg
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What types of patients are qualified to join this clinical research program?
"In order to be a part of this research, prospective patients must suffer from motion sickness and fall within the age bracket of 18-65. The goal is to recruit 30 people in total for the study."
What is the current enrollment capacity for this scientific research?
"Yes, information on clinicaltrials.gov confirms that this medical trial is actively receiving applicants. First posted on January 21st 2022 and last modified May 23rd 2023, the study aims to recruit 30 individuals at one clinic site."
Are there any openings left for prospective volunteers to join this experiment?
"According to clinicaltrials.gov, this trial is now in the process of patient enrollment and was initially posted on January 21st 2022. The most updated information has been added as recent as May 23rd 2023."
Does the trial accept participants aged 25 and above?
"The eligibility criteria for this medical trial restricts applicants to between 18 and 65 years old. Separately, there are 1 study available to minors and 4 studies open to seniors."
Has the FDA officially sanctioned DPI-386 Nasal Gel?
"Despite the lack of data regarding efficacy, there is sufficient evidence to consider DPI-386 Nasal Gel's safety as a 2 on our team's scale."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger